Who Paid My Doc
A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus
Research payments
$1,754,340
Through program year 2025, $1,754,340 in research payments was reported against A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus, across 40 payments, paid by Amgen Inc..
- Paid by
- Amgen Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
1 row| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $1,754,340 | 40 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Rupal Trivedi Saint Louis, MO Named on 3 payments
- Christopher Romero Houston, TX Named on 2 payments
- Kenneth Kim Long Beach, CA Named on 2 payments
- Ingrid Brown Beavercreek, OH Named on 2 payments
- Apinya Vutikullird Cypress, CA Named on 2 payments
- Timothy Smith Saint Peters, MO Named on 2 payments
- David Fitz-Patrick Honolulu, HI Named on 2 payments
- Adil Fatakia Marrero, LA Named on 2 payments
- Jeffrey Hopland Johnson City, TN Named on 2 payments
- Joel Neutel Tustin, CA Named on 2 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.